ReviewInternational immunopharmacology2021
COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.
Review in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Hyperimmune immunoglobulin for people with COVID-19.The Cochrane database of systematic reviews · 2023Pooled it
- Sterility, safety, and preventive efficacy of three polyvalent hyperimmune sera against bacterial infection in a white mouse challenge model.Frontiers in veterinary science · 2026Article
- SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity.iScience · 2024Article
- Assessment of health impacts in retired antisera-producing horses: Blood biochemistry and serum amyloid A analysis.Veterinary world · 2024Article
- An overview on the treatments and prevention against COVID-19.Virology journal · 2023Review
- Influence of SARS-CoV-2 inactivation by different chemical reagents on the humoral response evaluated in a murine model.Molecular immunology · 2022Article
- A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa.Scientific reports · 2022Article
- Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Review
- UsingExpert opinion on drug discovery · 2022Article
- Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera.Antibodies (Basel, Switzerland) · 2022Article
- Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.Toxicology and applied pharmacology · 2022Article
- Determination of Novel Coronavirus Disease (COVID-19) Vaccine Hesitancy Using a Systematic Review Approach Based on the Scientific Articles in PubMed Database.Turkish thoracic journal · 2022Article
- Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense.Bosnian journal of basic medical sciences · 2021Review
- Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives.International immunopharmacology · 2021Review
- Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19.Frontiers in medicine · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the very beginning of the COVID-19 pandemic, different treatment strategies have been explored. These mainly involve the development of antimicrobial, antiviral, and/or anti-inflammatory agents as well as vaccine production. However, other potential options should be more avidly investigated since vaccine production on a worldwide level, and the anti-vaccination movement, also known as anti-vax or vaccine hesitancy by many communities, are still real obstacles without a ready solution. This review presents recent findings on the potential therapeutic advantages of heterologous serotherapy for the treatment of COVID-19. We present not only the effective use in animal models of hyperimmune sera against this coronavirus but also strategies, and protocols for the production of anti-SARS-CoV-2 sera. Promising antigens are also indicated such as the receptor-binding domain (RBD) in SARS-CoV-2 S protein, which is already in phase 2/3 clinical trial, and the trimeric protein S, which was shown to be up to 150 times more potent than the serum from convalescent donors. Due to the high death rate, the treatment for those currently infected with coronavirus cannot be ignored. Therefore, the potential use of anti-SARS-CoV-2 hyperimmune sera should be carefully but urgently evaluated in phase 2/3 clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.